Organization
The Second Xiangya Hospital of Central South University
7 abstracts
Abstract
A potential best-in-class BCMA-CD19 bispecific CART with advanced safety by self-inhibiting IFNG signaling during CRS.Org: Celledit, The Third Affiliated Hospital of Southern Medical University, The First Affiliated Hospital of University of Science and Technology of China, The Second Xiangya Hospital of Central South University,
Abstract
Association between psychological distress and treatment efficacy in patients with newly diagnosed SCLC.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, The Second Xiangya Hospital of Central South University, Central South University, Changsha, China,
Abstract
Phase II study of durvalumab plus olaparib as maintenance therapy in extensive-stage small-cell lung cancer (TRIDENT): Preliminary efficacy and safety results.Org: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, Affiliated Dongguan Hospital, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital,
Abstract
Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).Org: Sun Yat-sen University Cancer Center Gansu Hospital, The Affiliated Cancer Hospital of Guangzhou Medical University, Fudan University Cancer Center, Cancer Center Union Hospital Tongji Medical College Huazhong University of Science and Technology, Affiliated Hospital of Guangdong Medical University,
Abstract
The analysis of BRAF fusions characteristics in Chinese solid tumor patients.Org: The Second Xiangya Hospital of Central South University, Nanjing Simcere Medical Laboratory Science Co., Ltd.,
Abstract
Antitumor regimens with gemcitabine are safe for tumor patients with COVID-19.Org: The Second Xiangya Hospital of Central South University, Central South University, Changsha, China,
Abstract
Washing solution of tissue biopsy compared with paraffin-embedded tissue for NSCLC gene test.Org: The Second Xiangya Hospital of Central South University, Central South University, Changsha, China, Changsha, China,